UY33241A - ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. - Google Patents

?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.

Info

Publication number
UY33241A
UY33241A UY0001033241A UY33241A UY33241A UY 33241 A UY33241 A UY 33241A UY 0001033241 A UY0001033241 A UY 0001033241A UY 33241 A UY33241 A UY 33241A UY 33241 A UY33241 A UY 33241A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
tienopyrimidines
containing heterocycloalkyl
compounds
relates
Prior art date
Application number
UY0001033241A
Other languages
English (en)
Inventor
Thorsten Lehmann-Lintz
Kley Joerg
Redemann Norbert
Sauer Achim
Thomas Leo
Wiedenmayer Dieter
Austen Matthias
Danilewicz John
Schneider Martin
Schreiter Kay
Black Phillip
Blackaby Wesley
Linney Ian
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43902874&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY33241A publication Critical patent/UY33241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se refiere a compuestos de tienopirimidina de fórmula I y a nuevas composiciones farmacéuticas que comprenden dichos compuestos. Además de ello, la presente invención se refiere al uso de los compuestos de tienopirimidina de la invención para la producción de composiciones farmacéuticas para la profilaxis y/o el tratamiento de enfermedades que pueden verse influenciadas por la inhibición de la actividad quinasa de Mnk1 y/o Mnk2 (Mnk2a o Mnk2b) y/o de variantes adicionales de las mismas.
UY0001033241A 2010-02-26 2011-02-24 ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. UY33241A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10154925 2010-02-26

Publications (1)

Publication Number Publication Date
UY33241A true UY33241A (es) 2011-09-30

Family

ID=43902874

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033241A UY33241A (es) 2010-02-26 2011-02-24 ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.

Country Status (15)

Country Link
US (1) US8648068B2 (es)
EP (1) EP2539346B1 (es)
JP (1) JP5639197B2 (es)
KR (1) KR20120130052A (es)
CN (1) CN102869669A (es)
AR (1) AR080327A1 (es)
AU (1) AU2011219761A1 (es)
BR (1) BR112012021264A2 (es)
CA (1) CA2791105A1 (es)
CL (1) CL2012002318A1 (es)
EA (1) EA201201193A1 (es)
MX (1) MX2012009409A (es)
TW (1) TW201141482A (es)
UY (1) UY33241A (es)
WO (1) WO2011104337A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006136402A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
EA200802118A1 (ru) * 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2010023181A1 (en) 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2547905T3 (es) * 2010-02-26 2015-10-09 Evotec International Gmbh 4-[Cicloalquiloxi(hetero)arilamino]-tieno[2,3-d]pirimidinas que tienen actividad inhibidora de la Mnk1/Mnk2 para composiciones farmacéuticas
MX2012009851A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
AR080314A1 (es) 2010-02-26 2012-03-28 Japan Tobacco Inc Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
EP2852595B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
CA2873975A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Thienopyrimidines
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN105377845B (zh) 2013-02-01 2017-11-24 拜耳制药股份公司 取代的吡唑并嘧啶基氨基‑吲唑类
US20160159816A1 (en) 2013-02-01 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
CN105308054B (zh) 2013-03-06 2017-11-21 拜耳制药股份公司 取代的噻唑并嘧啶
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN103356626B (zh) * 2013-08-02 2015-01-07 上海市第十人民医院 吡唑并嘧啶类化合物在制备抗红色毛癣菌感染疾病药物中的应用
CN103356624B (zh) * 2013-08-02 2014-12-31 上海市第十人民医院 一种嘧啶类化合物在制备抗真菌药物中的应用
CN103356628B (zh) * 2013-08-02 2014-10-29 上海市第十人民医院 嗓唑并嘧啶类化合物在制药中的应用
CN103356627B (zh) * 2013-08-02 2014-10-29 上海市第十人民医院 一种药物在光滑假丝酵母菌感染性疾病应用
CN103356625B (zh) * 2013-08-02 2014-10-29 上海市第十人民医院 嗓唑并嘧啶类在***滑假丝酵母菌感染性疾病应用
CN103417545B (zh) * 2013-08-02 2014-12-31 上海市第十人民医院 一种吡唑并嘧啶类化合物在制备抗烟曲霉菌感染性疾病药物中的应用
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3077383B1 (en) * 2013-12-04 2018-08-22 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) * 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
EP3140300B1 (en) * 2014-05-07 2019-08-14 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドＳｏｕｔｈ Ａｕｓｔｒａｌｉａｎ Ｈｅａｌｔｈ Ａｎｄ Ｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｌｉｍｉｔｅｄ 高脂肪食関連疾患を阻害する方法
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH408945A (de) 1956-02-10 1966-03-15 Ciba Geigy Verfahren zur Herstellung von heterocyclischen Verbindungen
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DD248593A1 (de) 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
CA2039411A1 (en) 1990-03-30 1991-10-01 Ronnie Gerald Edie Thienopyrimidine derivatives
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ATE159257T1 (de) * 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6643277B2 (en) 2000-06-29 2003-11-04 Harris Broadband Wireless Access, Inc. Frequency re-use for point to multipoint applications
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
MXPA03009925A (es) 2001-04-30 2004-06-30 Bayer Pharmaceuticals Corp Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas.
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
AU2002363175A1 (en) 2001-10-29 2003-05-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20050012622A1 (en) 2003-05-19 2005-01-20 Sutton William R. Monitoring and control of sleep cycles
US7589086B2 (en) 2003-05-28 2009-09-15 Universita Degli Studi Di Siena Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents
MXPA05013227A (es) 2003-06-20 2006-03-09 Celltech R&D Ltd Derivados de tienopiridona como inhibidores de cinasa.
WO2005010008A1 (en) 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
PL1703902T3 (pl) * 2004-01-05 2011-04-29 Merz Pharma Gmbh & Co Kgaa Memantyna do leczenia choroby Alzheimera o łagodnym do umiarkowanego stopniu zaawansowania
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
US20080269238A1 (en) * 2004-04-01 2008-10-30 Takeda Pharmaceutical Company Limited Thiazolopyrimidine Derivative
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
US7943357B2 (en) 2005-03-08 2011-05-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Crystallographic structure of Mnk-1 and Mnk-2 proteins
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2006136402A1 (en) 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
US20070099877A1 (en) * 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056214A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2007084815A2 (en) * 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
EA200802118A1 (ru) * 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
CA2706203A1 (en) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
CA2707046A1 (en) * 2007-11-28 2009-06-11 Nathanael S. Gray Small molecule myristate inhibitors of bcr-abl and methods of use
EP2458912B1 (en) * 2008-01-25 2014-06-04 Huawei Technologies Co., Ltd. Method and mobile station apparatus transmitting uplink data
US20100015708A1 (en) * 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
WO2010023181A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
WO2011104338A1 (en) 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
MX2012009851A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
ES2547905T3 (es) * 2010-02-26 2015-10-09 Evotec International Gmbh 4-[Cicloalquiloxi(hetero)arilamino]-tieno[2,3-d]pirimidinas que tienen actividad inhibidora de la Mnk1/Mnk2 para composiciones farmacéuticas
ES2583015T3 (es) * 2011-09-07 2016-09-16 Nordex Energy Gmbh Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

Also Published As

Publication number Publication date
BR112012021264A2 (pt) 2016-05-17
EP2539346A1 (en) 2013-01-02
AU2011219761A1 (en) 2012-08-16
US20110212102A1 (en) 2011-09-01
WO2011104337A1 (en) 2011-09-01
AR080327A1 (es) 2012-03-28
CL2012002318A1 (es) 2012-11-23
CA2791105A1 (en) 2011-09-01
TW201141482A (en) 2011-12-01
CN102869669A (zh) 2013-01-09
US8648068B2 (en) 2014-02-11
KR20120130052A (ko) 2012-11-28
EA201201193A1 (ru) 2013-04-30
JP2013520472A (ja) 2013-06-06
JP5639197B2 (ja) 2014-12-10
MX2012009409A (es) 2012-09-07
EP2539346B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
UY32072A (es) Tienopirimidinas para composiciones farmacéuticas
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
ECSP088875A (es) Tienopirimidinas con actividad inhibidora de mnk1/mnk2 para composiciones farmacéuticas
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
CR20150629A (es) Compuestos químicos
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
DOP2014000012A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
DOP2011000218A (es) Derivados de sulfonamida
UY32848A (es) Compuestos heterocíclicos de oxima
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
EA201390198A1 (ru) Гетероциклическое соединение
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CU20130170A7 (es) Pirrolotriazinas sustituidas con hidroximetilarilo
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
DOP2015000170A (es) Compuestos químicos
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
CR20160432A (es) Inhibidores de las vías de señalización de wnt
NI201200194A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191216